Current treatment of Cutaneous T-Cell Lymphoma.
Cutaneous T-cell lymphomas are a heterogeneous group of cutaneous non-Hodgkin's lymphomas. In the United States, the incidence of these diseases is rising faster than any other cancer. Environmental triggers may be important in the evolution of malignancy. Current therapy is reviewed with emphasis on a new retinoid, Targretin.
Duvic
M
M
University of Texas, MD Anderson Cancer Center, USA.
D000284:Administration, Oral; D000287:Administration, Topical; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D000077610:Bexarotene; D001706:Biopsy; D002330:Carmustine / Q000008:administration & dosage; D018450:Disease Progression; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D011701:PUVA Therapy; D011379:Prognosis; D012176:Retinoids / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000188:drug therapy / Q000276:immunology; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D014807:Vitamin D / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D014807:Vitamin D; D008466:Mechlorethamine; D000077610:Bexarotene; D002330:Carmustine